All In Biotech

Drug Trial Radar · NCT06194734

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Feb 5, 2024

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • KC1036Drug

    KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle

  • IrinotecanDrug

    Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks

  • DocetaxelDrug

    Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks;

  • S-1Drug

    S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Baseline to study completion (approximately 24 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.